Results 111 to 120 of about 3,103 (172)

Toward Precision Electrochemical Sensing of CFTR Function in Cystic Fibrosis Models. [PDF]

Anal Chem
Miglione A, Blaconà G, Singh S, Cicero SL, Fuso A, Cimino G, Eramo A, Malapelle U, Lucarelli M, Cinti S.   +9 more
europepmc   +1 more source

Risk of drug-related aggression in pediatric populations: a pharmacovigilance analysis using the FAERS database. [PDF]

Front Pediatr
Chen J, Zhao L.
europepmc   +1 more source

Sinonasal and Pulmonary Computed Tomography Images Before and After Triple-Combination Therapy in a Patient with Cystic Fibrosis Without ΔF508 Mutations. [PDF]

Diagnostics (Basel)
Tagliati C, Campagna G, Di Sabatino M, Lanni G, Battista D, Ripani P.   +5 more
europepmc   +1 more source

Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry. [PDF]

ERJ Open Res
Dillenhöfer S, Schütz K, Burkhart M, Ellemunter H, Kappler M, Sieber S, Naehrlich L, Brinkmann F, Sutharsan S.   +8 more
europepmc   +1 more source

Systematic Review of Nasal Endoscopy Scores in Cystic Fibrosis Patients Treated With Cystic Fibrosis Transmembrane Conductance Regulator Modulators. [PDF]

Pediatr Pulmonol
Gallardo R, Silva BS, Salgado LS, Ribeiro JD, Sakano E.   +4 more
europepmc   +1 more source

P454 Body composition and peripheral muscle function in people with cystic fibrosis established on elexacaftor/tezacaftor/ivacaftor

Peripheral muscle dysfunction is common amongst people with cystic fibrosis (CF) – the cause of which is multifactorial. Increasing numbers of people with CF are also overweight and obese, with early evidence suggesting those on the highly effective ...
Urquhart, Don S., Conett, Gary, Legg, Julian, Daniels, Thomas, Gruet, Mathieu, Allenby, Mark, Clayton, Lauren J., Corbett, Jo, Saynor, Zoe, Shepherd, Anthony I.   +9 more
core  

Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor-Tezacaftor-Ivacaftor-A Pilot Study. [PDF]

Int J Mol Sci
Sankararaman S, Liu R, Sun X, Retuerto M, Schindler T, Roesch E, Sferra TJ, Drumm M, Ghannoum M, Zhang L.   +9 more
europepmc   +1 more source

Comparative efficacy and safety of CFTR modulators for people with cystic fibrosis with phe508del mutation: a systematic review and bayesian network meta-analysis. [PDF]

EClinicalMedicine
Safeer V S M, Behl S, Vaidya PC, Tiwari P, Bharti SK, Nahan N, Kumar Sahu J, Bansal D.   +7 more
europepmc   +1 more source

The cystic fibrosis airway cytokine interleukin-1β enhances cystic fibrosis transmembrane conductance regulator modulator efficacy. [PDF]

ERJ Open Res
Gentzsch M, Boyles SE, Minges JT, Cholon DM, Okuda K, Ribeiro CMP.   +5 more
europepmc   +1 more source

AI-driven breathomics for early detection of CFTR modulator resistance in cystic fibrosis. [PDF]

Ann Med Surg (Lond)
Khan MH, Tariq AU, Cheema WA, Fatima M.
europepmc   +1 more source